Insider · CIK 0002050422

Bachrodt Amy

Reports to the SEC for 1 company · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0002050422

Forms 4 and 5

Insider transactions

40 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-04-01	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+2,500 sh	$10.42	+$26.1K	15,465
2026-04-01	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−2,500 sh	—	—	33,833
2026-04-01	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−300 sh	$30.34	−$9,101.01	12,965
2026-04-01	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−2,200 sh	$29.32	−$64.5K	13,265
2026-03-02	MAZEMaze Therapeutics, Inc. · Restricted Stock UnitsA Award	SVP, Finance	AAward	+16K sh	—	—	16,000
2026-03-02	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+5,000 sh	$10.42	+$52.1K	17,965
2026-03-02	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−1,300 sh	$44.44	−$57.8K	16,665
2026-03-02	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−3,700 sh	$45.47	−$168K	12,965
2026-03-02	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−5,000 sh	—	—	36,333
2026-03-02	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	SVP, Finance	AAward	+32K sh	—	—	32,000
2026-02-02	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+4,844 sh	$10.42	+$50.5K	17,809
2026-02-02	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−200 sh	$44.15	−$8,830	17,765
2026-02-02	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−156 sh	—	—	41,333
2026-02-02	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−4,844 sh	—	—	3,025
2026-02-02	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−736 sh	$46.63	−$34.3K	12,965
2026-02-02	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−4,064 sh	$46.03	−$187K	13,701
2026-02-02	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+156 sh	$10.42	+$1,625.52	17,965
2026-01-22	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+2,503 sh	$10.42	+$26.1K	17,965
2026-01-22	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−5,000 sh	$45.52	−$228K	12,965
2026-01-22	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−2,497 sh	—	—	486
2026-01-22	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−2,503 sh	—	—	7,869
2026-01-22	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+2,497 sh	$10.42	+$26K	15,462
2026-01-02	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−4,796 sh	—	—	2,983
2026-01-02	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−204 sh	—	—	2,377
2026-01-02	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+204 sh	$10.42	+$2,125.68	13,169
2026-01-02	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+4,796 sh	$10.42	+$50K	17,965
2026-01-02	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−2,405 sh	$38.70	−$93.1K	15,560
2026-01-02	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−2,595 sh	$39.57	−$103K	12,965
2025-12-30	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−2,395 sh	—	—	1
2025-12-30	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+2,395 sh	$10.42	+$25K	15,360
2025-12-30	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+2,605 sh	$10.42	+$27.1K	17,965
2025-12-30	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−5,000 sh	$40.08	−$200K	12,965
2025-12-30	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−2,605 sh	—	—	2,581
2025-12-29	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−9,876 sh	—	—	23,834
2025-12-29	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+124 sh	$10.42	+$1,292.08	13,089
2025-12-29	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Finance	MExercise/Conversion	−124 sh	—	—	2,396
2025-12-29	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−600 sh	$41.16	−$24.7K	12,965
2025-12-29	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	SVP, Finance	MExercise/Conversion	+9,876 sh	$10.42	+$103K	22,965
2025-12-29	MAZEMaze Therapeutics, Inc.S Sale	SVP, Finance	SSale	−9,400 sh	$40.54	−$381K	13,565
2025-09-22	MAZEMaze Therapeutics, Inc. · Restricted Stock UnitsA Award	SVP, Finance	AAward	+22K sh	—	—	22,000

Recent filings

Accepted (ET)
Apr 24
Bachrodt Amy0002050422-26-000012
SEC(opens sec.gov)
Mar 34
Bachrodt Amy0002050422-26-000010
SEC(opens sec.gov)
Feb 44
Bachrodt Amy0002050422-26-000008
SEC(opens sec.gov)
Jan 264
Bachrodt Amy0002050422-26-000005
SEC(opens sec.gov)

Companies

Maze Therapeutics, Inc.SVP, FinanceMAZE

Address

C/O MAZE THERAPEUTICS, INC. 171 OYSTER POINT BOULEVARD, SUITE 300

SOUTH SAN FRANCISCO, CA, 94080